U.S. vaccine developer Inovio Pharmaceuticals completed Phase II enrollment for a mid-to-late stage U.S. trial of the company’s Covid-19 vaccine candidate and expects to report data early in the second quarter.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-03-01 18:27:162021-03-01 19:31:59Inovio expects Covid-19 vaccine U.S. trial data by early second-quarter 2021
